Keywords: diffuse large B‐cell lymphoma (DLBCL). Disclosures: Kurukulasuriya, N: Employment Leadership Position: MorphoSys US Inc. Menzler, J: Research Funding: Morphosys AG. Neubauer, A: Research Funding: Morphosys AG. Boehnke, A: Employment Leadership Position: MorphoSys AG....
The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage therapy has been tried for these patients according to their clinical status. We studied ICD (irinotecan, cisplatin and dexamethasone) regimen as salvage chemotherapy ...
Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
e19531#Background:Central nervous system (CNS) relapse is an infrequent but serious and challenging complication in diffuse large B-cell lymphoma (DLBCL) that carries a dismal prognosis. While several risk factors have been identified to stratify the risk for CNS relapse including the 2015 CNS ...
TO THE EDITOR Primary cutaneous diffuse large B-cell lymphoma leg type (PCDLBCL-LT) is a unique entity (ICD-O code 9680/3) individualized from other primary cutaneous B-cell lymphomas (PCBCL) and from nodal B-cell lymphomas by three main clinical features: preferential leg localization, ...
Epidemiological insights and survival patterns of HHV8-positive diffuse large B-cell lymphoma (HDN) associated with multicentric Castleman disease (CD): A comprehensive analysis using SEER database.doi:10.1200/JCO.2024.42.16_suppl.e190801164
Patients with an ICD-10-CM diagnosis for DLBCL after October 2015 and no prior ICD-9-CM diagnosis for unspecified DLBCL or primary mediastinal large B-cell lymphoma (PMBCL) where classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of...
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP 来自 国家科技图书文献中心 喜欢 0 阅读量: 19 作者:HJ Kang,WS Kim,C Suh,YH Park,BS Kim,YJ Yuh,BY Ryoo ...
The VHA is an equal access system providing a unique environment to investigate cancer disparities across the disease continuum.Methods:This is a retrospective chart review of 4033 randomly selected patients with an ICD code for lymphoma treated within the VHA between 01/01/2011 and 12/31/2017. ...